Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01868451 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Study Title
Brentuximab Vedotin Combined With AVD Chemotherapy and Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (NCT01868451)

Trial Description
The purpose of this study is to find out whether brentuximab vedotin with AVD chemotherapy and radiation is a safe and effective treatment. It is hoped that this treatment will improve the ability to cure more patients with HL.

This trial is sponsored by Memorial Sloan Kettering Cancer Center [1]

Study Data

  • Condition: Hodgkin Lymphoma
  • Interventions:
  • Phase: 0
  • Estimated Enrollment: 59
  • Start: May 2013
  • Estimated Completion: May 2016
  • Last verified: May 2015

Study Schematic 

(NCT01868451 CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar